Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Technology, Consumer Services and Consumer Goods sectors led shares higher. At the close in...
Investing.com – U.S. stocks were higher after the close on Wednesday, as gains in the Technology, Industrials and Basic Materials sectors led shares higher. At the close in NYSE,...
September was another lackluster month for the stock market, with the S&P 500 dropping by over 9%. The healthcare sector, however, was among the best performing, with the...
PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced that the FDA has granted Breakthrough Therapy designation to its lead pipeline candidate, PB2452. The company is developing...
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.